Amarininvestor
“I am wondering though whether with the new extended label, Insurance companies would put EPA as a different category than omega-3 all together, So regardless of what the indication is (hyperT. or CVD) if a doctor writes Vascepa, the patient gets EPA and nothing else. IS that even possible at this stage?”
Bottom line is: No
Insurance companies, like all businesses are about making money, maximum profit and reduce expenses. Insurance companies are going to want the least expensive equivalent molecule (Vascepa or generic Vascepa which would have to be the identical molecule and same bioavailability).
The actual label doesn’t mean anything in the pharmacy sense. Docs use a label to define which pts are recommended by the FDA for treatment. Insurance use labels to define who should be covered. The label carries no similar meaning or significance in pharmacy. Doctor “A” prescribes drug “X” for Pt “B”. Pharmacist ensures the Pt knows what he is taking, how to get the most out of the medication and what side effects could occur and what to do if they arise. What the drug label is or says is not relevant to the act of dispensing because it could easily be “off label”.
This is why I can’t see how a carve out label could possibly work in the real world. If Dr Reddy gets a carve out label Amarin should fire all reps and move to Europe- the US market would be dead. This would be devastating for the pts in the US but you can’t expect Amarin to market a drug where all the sales will go to generics. This is really an all or nothing decision coming with the courts.
Merry Christmas and happy holidays to everyone! 2018 was a great year, 2019 was a letdown but 2020 will rock!
News 
Market Data 
Discover 
